Idoxifene
Alternative Names: CB 7432; Pyrrolidino-4-iodotamoxifen; SB 223030Latest Information Update: 02 Aug 2023
At a glance
- Originator Cancer Research UK Centre for Cancer Therapeutics
- Developer BTG; Cancer Research UK Centre for Cancer Therapeutics
- Class Stilbenes
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Postmenopausal osteoporosis
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 23 Jul 1999 Discontinued-II for Breast cancer in United Kingdom (PO)
- 23 Jul 1999 Discontinued-II for Breast cancer in USA (PO)